Impact of Long Term of Benzodiazepine Use on Psychiatric Manifestation

NCT04792658 | Unknown DMC

• 1 other identifier: long term of benzodiazepine
• Study Type: observational
• Target: 100
• Locations: 0 countries
• Sites: N/A

Brief Summary

Benzodiazepines are usually a secondary drug of abuse-used mainly to augment the high received from another drug or to offset the adverse effects of other drugs. Few cases of addiction arise from legitimate use of benzodiazepines. Pharmacologic dependence, a predictable and natural adaptation of a body system long accustomed to the presence of a drug, may occur in patients taking therapeutic doses of benzodiazepines. However, this dependence, which generally manifests itself in withdrawal symptoms upon the abrupt discontinuation of the medication, may be controlled and ended through dose tapering, medication switching, and/or medication augmentation. Due to the chronic nature of anxiety, long-term low-dose benzodiazepine treatment may be necessary for some patients; this continuation of treatment should not be considered abuse or addiction. previous study reported that The results of the study are important in that they corroborate the mounting evidence that a range of neuropsychological functions are impaired as a result of long-term benzodiazepine use, and that these are likely to persist even following withdrawal. The findings highlight the residual neurocognitive compromise associated with long-term benzodiazepine therapy as well as the important clinical implications of these results.

Conditions

Psychiatric Disorder; Benzodiazepine-Related Disorders

Keywords

psychiatric; benzodiazepine

Outcome Measures

Primary Outcomes (2)

• measure the prevalence of DSM 5 psychiatric disorders associated with long term of benzodiazepine use

  through study completion, an average of 1 year

• measure of risk factor of DSM 5 psychiatric disorders associated with long term of benzodiazepine use

  through study completion, an average of 1 year

Interventions

Detailed interview with personal demographic data BEHAVIORAL

, such as age, sex, education, history of occupation, past medical history, family history, medical, neurological, and psychiatric disorders.

Intelligence assessment using the Arabic version of the Wechsler Adult Intelligence Scale (WAIS) BEHAVIORAL

the test consists of six verbal subtests and five performance subtests. It used in measure Intelligence

The Arabic version of the Structured Interview for the Five-Factor Personality Model (SIFFM) BEHAVIORAL

it depend on a model of general language personality descriptors that based on theory suggests five broad dimensions to describe human personality

the Hamilton Depression Rating Scale BEHAVIORAL

it used for evaluation depression severity. It is 17 items and each item's score (0-4). with a total score range of 0-54

The Hamilton Anxiety Rating Scale BEHAVIORAL

it used for evaluation the severity of anxiety. The scale consists of 14 items and each item is scored on a scale from 0 to 4 , with a total score range of 0-56

The Minnesota Multiphasic Personality Inventory-2 (MMPI-2) BEHAVIORAL

It used to evaluate range of symptoms of psychopathology and personality traits that are maladaptive. It has 10 clinical scales subscales included the following: 1, hypochondriasis (Hs); 2, depression (D); 3, hysteria (Hy); 4, psychopathic deviation (Pd); 5, masculinity-femininity (Mf); 6, paranoia (Pa); 7, psychophrenia (Pt); 8, schizophrenia (Sc); 9, hypomania (Ma); 10, social introversion (Ma); (Si). More than 65 responses were considered symptomatic

Eligibility Criteria

• Age: 18 Years - 50 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64)
• Sampling Method: Probability Sample

Study Population

participants who have use benzodiazepine more than 1 year and attend in outpatient clinic in Neuropsychiatric department will be included.

You may qualify if:

• age from 18 years to 50 years
• No history of neurological or medical illness

You may not qualify if:

• intelligence score more than 80

Sponsors & Collaborators

• Assiut University: lead

Related Publications (3)

• Shinfuku M, Kishimoto T, Uchida H, Suzuki T, Mimura M, Kikuchi T. Effectiveness and safety of long-term benzodiazepine use in anxiety disorders: a systematic review and meta-analysis. Int Clin Psychopharmacol. 2019 Sep;34(5):211-221. doi: 10.1097/YIC.0000000000000276.

  PMID: 31274696 RESULT

• O'brien CP. Benzodiazepine use, abuse, and dependence. J Clin Psychiatry. 2005;66 Suppl 2:28-33.

  PMID: 15762817 RESULT

• Crowe SF, Stranks EK. The Residual Medium and Long-term Cognitive Effects of Benzodiazepine Use: An Updated Meta-analysis. Arch Clin Neuropsychol. 2018 Nov 1;33(7):901-911. doi: 10.1093/arclin/acx120.

  PMID: 29244060 RESULT

MeSH Terms

Conditions

Mental Disorders

Central Study Contacts

gellan Ahmed

CONTACT

+201093663928; gillankaram@aun.edu.eg

Study Design

• Study Type: observational
• Observational Model: CASE CONTROL
• Time Perspective: CROSS SECTIONAL
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: lecturer, resarcher OF Neurology and Psychiatry department

Study Record Dates

• First Submitted: March 8, 2021
• First Posted: March 11, 2021
• Study Start: March 10, 2021
• Primary Completion: June 20, 2022
• Study Completion: September 20, 2023
• Last Updated: March 11, 2021

Record last verified: 2021-03

Data Sharing

• IPD Sharing: Will not share